Quality Control of Motor Unit Number Index (MUNIX) Measurements in 6 Muscles in a Single-Subject “Round-Robin” Setup

Christoph Neuwirth1*, Christian Burkhardt1, James Alix2, José Castro3, Mamede de Carvalho3, Malgorzata Gawel4, Stephan Goedee5, Julian Grosskreutz6, Timothée Lenglet7, Cristina Moglia8, Taha Omer9, Maarten Schrooten10, Markus Weber1,11

1 Neuromuscular Diseases Unit / ALS Clinic, Kantonsspital St.Gallen, St.Gallen, Switzerland, 2 Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, England, 3 Department of Neurosciences, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 4 Department of Neurology, Medical University of Warsaw, Warsaw, Poland, 5 Brain Centre Rudolf Magnus, Department of Neurology and Neurosurgery, UMC Utrecht, Utrecht, The Netherlands, 6 Hans-Berger Department of Neurology, University Hospital Jena, Jena, Germany, 7 Département de Neurophysiologie, Groupe hospitalier Pitié-Salpêtrière, APHP, Paris, France, 8 ALS Center of Torino, Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy, 9 Trinity College Biomedical Science Institute (TBSI) and Beaumont Hospital, Dublin, Ireland, 10 Department of Neurology, University Hospital Leuven, Leuven, Belgium, 11 Department of Neurology, University Hospital Basel, Basel, Switzerland

* christoph.neuwirth@kssg.ch

Abstract

Background

Motor Unit Number Index (MUNIX) is a neurophysiological measure that provides an index of the number of lower motor neurons in a muscle. Its performance across centres in healthy subjects and patients with Amyotrophic Lateral Sclerosis (ALS) has been established, but inter-rater variability between multiple raters in one single subject has not been investigated.

Objective

To assess reliability in a set of 6 muscles in a single subject among 12 examiners (6 experienced with MUNIX, 6 less experienced) and to determine variables associated with variability of measurements.

Methods

Twelve raters applied MUNIX in six different muscles (abductor pollicis brevis (APB), abductor digiti minimi (ADM), biceps brachii (BB), tibialis anterior (TA), extensor dig. brevis (EDB), abductor hallucis (AH)) twice in one single volunteer on consecutive days. All raters visited at least one training course prior to measurements. Intra- and inter-rater variability as determined by the coefficient of variation (COV) between different raters and their levels of experience with MUNIX were compared.
Results

Mean intra-rater COV of MUNIX was 14.0% (±6.4) ranging from 5.8 (APB) to 30.3% (EDB). Mean inter-rater COV was 18.1 (±5.4) ranging from 8.0 (BB) to 31.7 (AH). No significant differences of variability between experienced and less experienced raters were detected.

Conclusion

We provide evidence that quality control for neurophysiological methods can be performed with similar standards as in laboratory medicine. Intra- and inter-rater variability of MUNIX is muscle-dependent and mainly below 20%. Experienced neurophysiologists can easily adopt MUNIX and adequate teaching ensures reliable utilization of this method.

Introduction

Motor Unit Number Index (MUNIX) is a novel variant of motor unit number estimation (MUNE) techniques which provides an index of the number of functional lower motor neurons in a muscle. Recent studies have suggested that this technique may serve as a marker of disease progression in diseases with progressive loss of motor units, such as amyotrophic lateral sclerosis (ALS). Several studies have also demonstrated a good test-retest reliability in healthy subjects and ALS patients. [1–7]

Sensitive biomarkers in early phase II ALS trials are sorely needed to reveal potential beneficial effects of therapeutic interventions. [8] Biomarkers directly linked to the fundamental underlying disease process, which in the case of ALS is the loss of motor neurons over time, would be advantageous. An important attribute of any biomarker is not only its sensitivity to change, but also reliability of measurements, which will allow a reduction in sample size and increase power to detect significant differences in ALS trials. [9] In laboratory medicine assessment of inter-centre variability can be relatively easily achieved with so called “round robin” tests. [10] A well-defined sample is sent to different laboratories which then perform a test-retest and compare the results with a reference value.

This kind of quality control is difficult to achieve in outcome measures or biomarkers which are linked to the performance of the test subject and/or rater. However, a pivotal study of the forced vital capacity in a large multi-centre trial clearly showed that after adequate training an excellent inter-rater reliability can be achieved. [11] Such an approach has never been used for neurophysiological measures or neuroimaging. Over the past few years, several European centres have been trained to undertake the novel MUNIX method as part of the SOPHIA (Sampling and biomarker OPtimization and Harmonization In ALS and other motor neuron diseases) project. A refresher course held during the ENCALS meeting in Dublin 2015 offered a unique opportunity to perform a “round robin” test on a single subject. The goal was to evaluate MUNIX variability among 12 raters and to analyse associated factors.

Subjects and Methods

At the ENCALS (European Network for the Cure of ALS) meeting in Dublin 2015, a MUNIX training course was held over 2 days. Neurophysiologists from different European countries already familiar with this method and who had previously attended one or more training courses were invited. Twelve raters were included, 6 of them had passed a qualification process as part of a longitudinal study (SOPHIA). For this qualification process, raters had to perform
MUNIX measurements in 6 muscles (Mm. abductor digiti minimi, abductor pollicis brevis, biceps brachii, tibialis anterior, extensor digitorum brevis and abductor hallucis) in 4 healthy volunteers in two separate sessions. Raw data and results were sent to one reviewer (C.N.) and raters were certified when measurements showed a coefficient of variation (COV) below 20%.

During the round robin study, all 12 raters measured above mentioned muscles in one healthy subject (M.W.) in two sessions. Test and retest session were separated by one day. No specific sequence of raters was determined but the order was kept the same on the 2 consecutive days. A Dantec Keypoint Focus EMG system was used with clamp cables and self-adhesive Kendall™ Nutab electrodes with 15 mm diameter for recordings. Electrodes and marks were completely removed between each rater. Raters were timed during the recording and allowed a maximum of 5 minutes on a single muscle. MUNIX values of recordings were calculated separately after the recording process.

MUNIX applies a statistical approach, using the area and power of the supramaximal stimulated compound muscle action potential (CMAP) and area and power of the surface electromyography with different force levels of voluntary isometric activation. With these values the ‘ideal case motor unit count’ is computed to estimate the amount motor neurons, reflected by an index value. The method has been described in detail. [3, 12]

Electrode placement and electrical supramaximal nerve stimulation was performed according to standard neurographic procedures. A mandatory step was to reposition the recording electrode over the muscle belly several times to obtain the highest CMAP amplitude. Details of electrode placements including photo material are available online at http://www.encals.eu/page/european-collaborative-projects.

The protocol for MUNIX test-retest measurements in healthy volunteers was approved by the Ethics Committee St.Gallen previously. [6] The single test subject (M.W.) gave written informed consent to participate during the ENCALS meeting and MUNIX training course. According to the Swiss regulations, no separate ethical approval was needed for observational single case studies in a healthy subject.

In advance of the meeting, raters were sent a questionnaire regarding their general experience in electrophysiology, percent of daily time devoted to electrophysiology and nerve conduction studies (NCS), number of prior performed MUNIX measurements, number of MUNIX training sessions undertaken and what they felt would be the two most difficult muscles to measure. Variables assessed during the MUNIX measurements included procedure time and maximum electric stimulation intensity for each single measurement.

Since a systematic error (e.g. non-optimal CMAP amplitude) may not necessarily affect the test-retest reliability but accuracy, in addition a hypothetical reference value was determined for each muscle. For this reference value, the 6 largest CMAPs (mean of test-retest measurements) were determined for each muscle. Of these 6 test-retest measurements, the 3 test-retest measurements with the lowest CMAP variability were selected to calculate the “reference” CMAP amplitudes and the corresponding MUNIX values (mean of 3 measurements).

The muscle-specific difference between real measurements and reference value was determined for all raters (accuracy).

Statistics
To evaluate the reliability of MUNIX and CMAP measurements, the coefficient of variation (COV: 100 * SD/mean) and variability (VAR: 100 * difference of test-retest/mean) were determined for each muscle. Intra-class correlation coefficient values turned out to be unfavourable because of the special situation of only one study subject yielding inter-subject variabilities near zero. Depending on the comparisons Welch’s t-test, paired t-test, (nested) linear mixed-
effects models with "Rater" as random effect and linear regressions were performed as indicated in the results.

All analyses were performed using the statistical programme R Version 2.15.2. [12]

Results

MUNIX was well tolerated in the single subject, even when a total of 144 measurements were performed over 2 days. One rater (rater 5) was unsuccessful in obtaining a proper biceps CMAP on the first measurement. As per protocol the recording was aborted after 5 minutes. Otherwise, no major technical issues occurred.

Table 1 shows the characteristics of raters. Raw data are listed in the S1 Table.

All raters specified prior to the study which two muscles they felt to be most challenging. The biceps muscle was mentioned most frequently, followed by the M. abductor hallucis. (Table 1)

Reliability

Test-retest data and coefficients of variation (COV) for MUNIX measurements in individual muscles are summarized in Fig 1 and Tables 2 and 3, respectively.

Intra-rater coefficient of Variation (COV) ranged from 7.4 (APB) to 24.3 (EDB). Range was smaller in the experienced group (8.5 (ADM) and 18.9 (TA)) with a mean of 13.4 (SD ± 4.5) compared to the less experienced group (5.8 (APB) to 30.3 (EDB), mean 14.7 (SD ± 8.4)). The EDB showed comparably low MUNIX values (mean MUNIX 69 ± 16) compared to the MUNIX values of other 5 muscles (mean 192 ± 35), which contributes to a relatively higher COV.

Inter-rater reliability differed muscle-specific considering both measurements and ranged from 8.0 to 31.7 (mean 18.1± 5.4) (Table 3). The biceps exhibited the lowest overall inter-rater variability, the AH the largest (means of measurements). With the exception of the AH, all other muscles revealed inter-rater COV equal or below 20%.

Table 1. Characteristics of raters familiar (1 to 6) and less familiar (7 to 12) with the MUNIX method. # = number.

| rater | experience neurophys. [years] | daily time neurophy [%] | NCS per week [#] | experience neurophys. of MUNIX [months] | MUNIX / muscle [#] | challenging muscle 1 | challenging muscle 2 | MUNIX courses [#] |
|-------|-----------------------------|-------------------------|------------------|----------------------------------------|-------------------|---------------------|---------------------|-------------------|
| 1     | 12                          | 25–50%                  | 26–50            | 84                                     | >100              | AH                  | Biceps             | 4                 |
| 2     | 9                           | 25–50%                  | 26–50            | 30                                     | 51–100            | AH                  | TA                 | 3                 |
| 3     | 11                          | >75%                    | 51–100           | 72                                     | >100              | Biceps             | AH                 | 2                 |
| 4     | 3                           | >75%                    | 11–25            | 17                                     | 26–50             | Biceps             | AH                 | 1                 |
| 5     | 15                          | 50–75%                  | 26–50            | 17                                     | >100              | Biceps             |                     | 2                 |
| 6     | 3                           | 25–50%                  | 26–50            | 24                                     | >100              | EDB                 |                     | 1                 |
| 7     | 25                          | 50–75%                  | 26–50            | 36                                     | 11–25             | AH                  |                     | 3                 |
| 8     | 15                          | 10–25%                  | 11–25            | 12                                     | 1–10              | EDB                 | Biceps             | 2                 |
| 9     | 8                           | <10%                    | 11–25            | 5                                      | 11–25             | AH                  | Biceps             | 2                 |
| 10    | 10                          | 50–75%                  | 26–50            | 36                                     | 11–25             | Biceps             |                     | 1                 |
| 11    | 4                           | 25–50%                  | 11–25            | 10                                     | 26–50             | EDB                 | Biceps             | 1                 |
| 12    | 10                          | 25–50%                  | 51–100           | 24                                     | 11–25             | AH                  | Biceps             | 1                 |

mean 10.4 25–50% 30.6 26–50 * 1.9

SD (± 6.2) (± 24.3) (± 1.0)

* = median

doi:10.1371/journal.pone.0153948.t001
Fig 1. A and B: Test-retest results for MUNIX (A) and CMAP (mV) (B) in individual muscles. The dotted lines indicate the hypothetical reference value. Note the different y-axis scales for each muscle. Open dots = test values, filled dots = retest values.

doi:10.1371/journal.pone.0153948.g001
Analysing the difference between MUNIX and CMAP measurements and the arbitrary reference value revealed a high accuracy (relative mean) and good reliability (SD) of measurements. (Fig 2)

Among the 12 individual raters, intra-rater COV of all MUNIX measurements ranged from 6.6 to 22.9 (mean 14.1 ± 4.3, data not shown).

In univariate linear mixed-effects models, no significant influence on the variability of MUNIX and CMAP measurements was present for general neurophysiological experience (years), amount of clinical electrophysiology in daily practice, experience in MUNIX (months) and number of attended MUNIX training courses (data not shown).

Between the experienced and less experienced group, no significant differences were observable for MUNIX, CMAP, time and maximum stimulation intensity determined by Welch’s t-tests (p values > 0.22, not shown in Table 4). One rater in the experienced group used habitually higher stimulation intensities (up to 85 mA) compared to all other raters, leading to a trend of slightly higher stimulation intensities in the experienced group.

Retests the following day were generally performed 0.6 minutes faster (all 6 muscles together) (p = 0.001, paired t-test). A more detailed analysis by a nested linear mixed effects model revealed that only the AH and TA differed significantly (p = 0.027 and 0.006, respectively).

Longer duration of MUNIX measurements were correlated with higher stimulation intensities. (Fig 3) Linear regression of all measurements revealed a significant correlation (p < 0.001) between higher stimulation intensities and longer duration of measurements. Each increase of 10 mA is estimated with 0.34 minutes longer duration. This was also true when excluding all measurements with very high stimulation intensities > 50 mA (p < 0.001, 0.46 min per 10 mA increase).

### Table 2. Coefficient of variation (COV) and variability (SD) for MUNIX measurements in individual muscles in raters.

| muscle | intra-rater all raters (n = 12) | exp. raters (n = 6) | non-exp. raters (n = 6) |
|--------|-------------------------------|---------------------|-------------------------|
|        | COV MUNIX COV CMAP            | COV MUNIX COV CMAP  | COV MUNIX COV CMAP      |
| APB    | 7.4 (10.5) 4.2 (5.9)          | 9.0 (12.8) 3.3 (4.7) | 5.8 (8.2) 5.0 (7.1)     |
| ADM    | 10.7 (15.1) 4.2 (5.9)         | 8.5 (12.0) 2.4 (3.3) | 12.9 (18.3) 6.0 (8.5)   |
| BB     | 11.1 (15.6) 8.0 (11.3)        | 12.6 (17.8) 14.1 (19.9) | 8.9 (13.9) 2.9 (4.2) |
| TA     | 16.6 (23.5) 9.9 (14.0)        | 18.9 (26.7) 10.9 (15.4) | 14.4 (20.3) 9.0 (12.7) |
| EDB    | 24.3 (34.4) 4.7 (6.7)         | 18.4 (26.0) 4.9 (6.9) | 30.3 (42.8) 4.6 (6.5)   |
| AH     | 13.9 (19.6) 6.2 (8.8)         | 13.0 (18.4) 6.1 (8.6) | 14.8 (20.9) 6.3 (8.9)   |

### Table 3. Inter-rater variability (COV) in individual muscles for the first and second measurement and mean of both values.

| muscle | 1st measurement | 2nd measurement | mean of measurements |
|--------|-----------------|-----------------|----------------------|
|        | COV MUNIX COV CMAP | COV MUNIX COV CMAP | COV MUNIX COV CMAP |
| APB    | 16.4 6.7         | 14.1 5.6         | 13.5 4.9             |
| ADM    | 18.9 7.7         | 17.8 8.2         | 15.9 7.4             |
| BB     | 8.0 11.6         | 16.8 9.2         | 8.1 8.5              |
| TA     | 20.3 12.9        | 16.4 7.0         | 10.9 6.9             |
| EDB    | 18.0 9.8         | 20.0 9.5         | 12.2 8.4             |
| AH     | 19.2 13.0        | 31.7 11.4        | 22.8 11.3            |

doi:10.1371/journal.pone.0153948.t002
doi:10.1371/journal.pone.0153948.t003
Fig 2. Relative mean and standard deviation of MUNIX and CMAP measurements in individual muscles of the experienced group (filled circles) and less-experienced group (empty circles) compared to the hypothetical reference values, expressed as accuracy (%).

doi:10.1371/journal.pone.0153948.g002

Table 4. Descriptive results of MUNIX and CMAP measurements in different rater groups.

| Muscle | all raters (n = 12) | experienced raters (n = 6) | non-experienced raters (n = 6) |
|--------|---------------------|---------------------------|-------------------------------|
|        | MUNIX mV | time (min) | max. stim. (mA) | MUNIX mV | time (min) | max. stim. (mA) | MUNIX mV | time (min) | max. stim. (mA) |
| APB    | 192 (29) | 10.6 (0.7) | 3.2 (1.2) | 28.3 (17.7) | 199 (27) | 10.6 (0.5) | 3.2 (1.4) | 28.9 (18.1) | 186 (30) | 10.6 (0.8) | 3.3 (1.1) | 27.6 (18.0) |
| ADM    | 183 (33) | 12.0 (1.0) | 3.6 (1.3) | 21.9 (10.7) | 176 (22) | 12.2 (0.7) | 3.5 (1.1) | 25.0 (13.0) | 190 (41) | 11.9 (1.3) | 3.8 (1.5) | 18.9 (7.1)  |
| BB     | 218 (30) | 9.7 (0.6)  | 3.5 (0.9) | 34.3 (12.2) | 218 (33) | 9.4 (1.4)  | 3.8 (1.0) | 39.2 (15.1) | 218 (28) | 9.7 (0.6)  | 3.3 (0.9) | 29.8 (6.5)  |
| TA     | 145 (26) | 7.0 (0.7)  | 4.3 (1.4) | 23.4 (9.2)  | 144 (31) | 6.8 (0.8)  | 4.0 (1.1) | 24.9 (11.2) | 145 (22) | 7.1 (0.6)  | 4.7 (1.7) | 21.9 (6.8)  |
| EDB    | 69 (16)  | 4.7 (0.5)  | 4.9 (1.6) | 43.6 (14.8) | 69 (15)  | 4.8 (0.6)  | 5.0 (1.9) | 46.8 (19.1) | 68 (17)  | 4.6 (0.3)  | 4.9 (1.4) | 40.4 (8.6)  |
| AH     | 222 (57) | 13.1 (1.6) | 4.2 (1.4) | 34.9 (14.2) | 208 (67) | 13.2 (1.9) | 4.4 (0.9) | 37.4 (17.0) | 235 (43) | 13.1 (1.5) | 4.0 (1.8) | 32.4 (11.0) |

() = SD

doi:10.1371/journal.pone.0153948.t004
Discussion

Reliability and accuracy of measurements is a key feature of any biological marker of disease. While this is relatively easily determined and common in laboratory medicine, it is much more challenging with physiological measures as these factors depend on both the subject’s and rater’s performance. Moreover, individual subjects cannot easily been sent to different laboratories. A “round robin test” is commonly used to evaluate reliability of measurements for biochemical and other “wet biomarker” laboratory tests between centres. [10, 13] This study is unique in that for the first time both reliability and accuracy of an electrophysiological measurement (MUNIX) was determined in a “round robin” setup.

The most important finding in this study it that the COV both within raters (intra-rater variability) and between raters (inter-rater variability) is equal or below 20%. The only exceptions are the AH which revealed the highest inter-rater COV for CMAP and MUNIX, and the intra-rater COV for EDB MUNIX. This reliability compares favourably with e.g. “wet biomarkers” of neuronal death and axonal damage like neurofilament (NF) proteins in cerebrospinal fluid, which exhibited an inter-lab COV of 59%. [14] Given that for biomarker qualification processes, as implemented by the FDA and European Medicines Agency (EMA), performance
characteristics are also an important factor (www.fda.gov), we propose that regardless of the character of the biomarker (dry or wet), studies of inter and intra-rater reliability should be mandatory before such measures are taken up into clinical trials. [15, 16] Our study also provides evidence that reliability tests—as part of a quality control process—can be studied with reasonable costs and effort.

Previous data have suggested that intra- and inter-rater test-retest reliability of the MUNIX method is dependent on individual rater's experience. [1, 2, 4–6, 17] In two multicentre MUNIX studies in healthy subjects and ALS patients, test-retest variability decreased in the second study in the same raters. [5, 6] In this study, no significant difference between trained raters less familiar with the MUNIX method and raters with several experiences in MUNIX was observed, suggesting that the method itself is robust and can be easily adopted. General electrophysiological practice seemed not to influence MUNIX reliability. However, all participants had several years of electrophysiological experience and at least one intense whole-day training course (theoretic aspects and hands-on training). This suggests that with appropriate training, MUNIX might be adopted with sufficient reliability in EMG labs.

It would be desirable to perform the same study setup with an ALS patient. However, for ethical reasons it seems inappropriate to perform 144 measurements in a patient over 2 days. From previous studies it is known that test-retest reliability is similar in ALS patients compared to healthy subjects. [5, 18] This suggests that this method can be applied reliably in ALS patients.

The AH muscle showed a tendency of lower CMAP and greater range of MUNIX and CMAP values and therefore lower accuracy when applying a hypothetical reference value. One reason might be that CMAP amplitude over AH is generated by multiple muscles after supra-maximal tibial nerve stimulation and SIP recordings are mostly performed with voluntary toe flexion, as exclusive abduction of the hallucis is rarely obtainable. [19] It has also been demonstrated that MUNIX values are dependent of the direction of movement, which in total makes this muscle comparably unfavourable. [5, 20, 21]

The relative high MUNIX variability of the EDB muscle is most likely caused by comparably low absolute values. The volunteer exhibited a clearly damaged and atrophic EDB on the contralateral side; consequently, a bilateral (and before that date unrecognised) damage of the distal motor branch of the deep peroneal nerve might be the reason.

Single measurements were generally fast to perform in less than 5 minutes, with no significant difference between the experienced and less experienced group. We found a significant correlation of longer duration of measurements with increased stimulation intensities. This was visible in all 6 muscles, particularly in the biceps muscle, as electrical stimulation of the musculocutaneous nerve solely without co-stimulation of adjacent nerves is technically challenging. The most likely explanation is that raters, who had difficulties optimizing electrode position for maximum CMAP amplitude or finding the optimal stimulation electrode placement, tended to use higher electrical stimulation to ensure supramaximal nerve stimulation.

There are some limitations of this study. First, the test subject was not the typical volunteer and already familiar with this method. A "learning effect" seems possible, as MUNIX needs active cooperation of the test subject and so the study volunteer may have provided more consistent recruitment patterns than a typical study participant. Additionally, the environmental conditions were the same for all raters (EMG equipment and software, recording electrodes, filter settings), which might not be always the case in multicentre trials. Furthermore, less experienced raters performed measurements during or immediately after the training session. It is unclear, if the performance of these raters will persist when returning to their own EMG laboratory. In the aforementioned SOPHIA project, several raters failed to pass the qualification process at the first attempt. Therefore, we recommend continuous practice of this method.
prior to a reliability qualification process. The same would apply before this method is utilized in clinical trials, like in a previous MUNE study. [22]

**Conclusion**

In conclusion, quality control of MUNIX shows that this is a reliable and robust electrophysiological method with high accuracy. Our data suggest that experienced neurophysiologists can easily utilize this method after appropriate training. Round robin tests can be implemented with reasonable effort to neurophysiological techniques.

**Supporting Information**

S1 Table. Raw data. Units of parameter: „time” = minutes; „CMAP” = mV; MUSIX = Motor Unit Size Index (μV); „stim” = stimulation intensity in mA; yellow fields = missing data.

(DOCX)

**Acknowledgments**

We like to thank Dr Markus Weber for participating as volunteer. We are thankful to Urs Simmen (Simmen Statistical Consulting, Basel, Switzerland) for performing the statistical analysis.

**Author Contributions**

Conceived and designed the experiments: CN MW CB. Performed the experiments: CN MW CB JA JC MdC MG SG JG TL CM TO MS. Analyzed the data: CN MW CB MdC. Contributed reagents/materials/analysis tools: CN MW CB. Wrote the paper: CN MW CB JA JC MdC MG SG JG TL CM TO MS.

**References**

1. Ahn SW, Kim SH, Kim JE, Kim SM, Kim SH, Park KS, et al. Reproducibility of the motor unit number index (MUNIX) in normal controls and amyotrophic lateral sclerosis patients. Muscle Nerve. 2010; 42(5):806–13. doi: 10.1002/mus.21765 PMID: 20976784
2. Boekestein WA, Schelhaas HJ, van Putten MJ, Stegeman DF, Zwarts MJ, van Dijk JP. Motor unit number index (MUNIX) versus motor unit number estimation (MUNE): A direct comparison in a longitudinal study of ALS patients. Clin Neurophysiol. 2012.
3. Nandedkar SD, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010; 42(5):798–807. doi: 10.1002/mus.21824 PMID: 20976783
4. Nandedkar SD, Barkhaus PE, Stalberg EV. Reproducibility of MUNIX in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2011; 44(6):919–22. doi: 10.1002/mus.22204 PMID: 21953206
5. Neuwirth C, Barkhaus PE, Burkhardt C, Castro J, Czell D, de Carvalho M, et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J NeurolNeurosurgPsychiatry. 2015.
6. Neuwirth C, Nandedkar S, Stalberg E, Barkhaus PE, de Carvalho M, Furtula J, et al. Motor Unit Number Index (MUNIX): a novel neurophysiological marker for neuromuscular disorders; test-retest reliability in healthy volunteers. Clin Neurophysiol. 2011; 122(9):1867–72. doi: 10.1016/j.clinph.2011.02.017 PMID: 21936884
7. Neuwirth C, Nandedkar S, Stalberg E, Weber M. Motor unit number index (MUNIX): a novel neurophysiological technique to follow disease progression in amyotrophic lateral sclerosis. Muscle Nerve. 2010; 42(3):379–84. doi: 10.1002/mus.21707 PMID: 20589888
8. Shefner JM, Mihaila D. Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference? Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(5–6):337–43. doi: 10.3109/21678421.2014.918150 PMID: 24918689
9. Cudkowicz ME, Katz J, Moore DH, O’Neill G, Glass JD, Mitsumoto H, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11(3):259–65. doi: 10.3109/17482960903358865 PMID: 19961263
10. Bundesärztekammer (German Medical Association) IeV. Guidelines of the German Medical Association on quality assurance in medical laboratory testing. GMS Z Forder Qualitatssich Med Lab. 2015; 6:1–43.

11. Sanjak M, Salachas F, Frija-Orvoen E, Theys P, Hutchinson D, Verheijde J, et al. Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11(4):383–8. doi:10.3109/17482960903486083 PMID: 20192884

12. Nandedkar SD, Nandedkar DS, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX). IEEE TransBiomedEng. 2004; 51(12):2209–11.

13. Gunter EW, Bowman BA, Caudill SP, Twite DB, Adams MJ, Sampson EJ. Results of an international round robin for serum and whole-blood folate. Clin Chem. 1996; 42(10):1689–94. PMID: 8855155

14. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, et al. Neurofilament ELISA validation. J Immunol Methods. 2010; 352(1–2):23–31. doi:10.1016/j.jim.2009.09.014 PMID: 19857497

15. Manolis E, Vamvakas S, Isaac M. New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin Appl. 2011; 5(5–6):248–55. doi: 10.1002/prca.201000130 PMID: 21538915

16. Woodcock J, Buckman S, Goodsaied F, Walton MK, Zineh I. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. Expert Opin Med Diagn. 2011; 5(5):369–74. doi: 10.1517/17530059.2011.588947 PMID: 23484625

17. Furtula J, Johnsen B, Christensen PB, Pugdahl K, Bisgaard C, Christensen MK, et al. MUNIX and incremental stimulation MUNE in ALS patients and control subjects. Clin Neurophysiol. 2013; 124 (3):610–8. doi: 10.1016/j.clinph.2012.08.023 PMID: 23040293

18. Fathi D, Mohammadi B, Dengler R, Boselt S, Petri S, Kollewe K. Lower motor neuron involvement in ALS assessed by motor unit number index (MUNIX): Long-term changes and reproducibility. Clin Neurophysiol. 2016; 127(4):1984–8. doi: 10.1016/j.clinph.2015.12.023 PMID: 26971480

19. Nandedkar SD, Barkhaus PE. Contribution of reference electrode to the compound muscle action potential. Muscle Nerve. 2007; 36(1):87–92. PMID: 17455266

20. Zhou P, Li X, Rymer WZ. Computing motor unit number index of the first dorsal interosseous muscle with two different contraction tasks. Med Eng Phys. 2012; 34(8):1209–12. doi: 10.1016/j.medengphy.2012.06.011 PMID: 22818404

21. Zhou P, Nandedkar SD, Barkhaus PE. Voluntary contraction direction dependence of motor unit number index in patients with amyotrophic lateral sclerosis. IEEE TransNeural SystRehabilEng. 2014; 22 (5):992–6.

22. Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011; 77(3):235–41. doi: 10.1212/WNL.0b013e318225aabf PMID: 21676915